Phase II/III assets for anti-PD-1 resistant patients: LB1410 (Keytruda/anti-TIM-3 bsAb) and LB4330 (long-acting IL-10) are available for out-licensing, with a particular interest in finding partners in the U.S.:

LB1410: potential the next generation of K, great safety profile and promising efficacy (LB1410 monotherapy)

• a DCR (SD/PR) of 50%-70% across various anti-PD-1 resistant solid tumors, particularly,
• ORR for anti-PD-1 resistant Cervical Cancer (CC): 38.5% (5/13, 4PR, 1CR), DCR 69.2% (9/13). SOC（chem): ORR 6%
• ORR for anti- PD-1 resistant Renal Cell Carcinoma (RCC）: 14.3% (1/7), DCR 85.7% (6/7).
• Phase II/III (LB1410+Lenvatinib) +/- LB4330 for anti-PD1 resistant CC ongoing in China.

LB4330 in combo with LB1410: ORR for anti- PD-1 resistant RCC (IMDC favorable risk）: 40% (2/5), DCR 80% (4/5).

Both LB1410 and LB4330 have received FDA IND approval. IP granted.

We are currently NOT seeking any CROs or CDMOs at this meeting.

Thanks

CEO, BD head, L&L Bio, China